4.50
4.50 (0%)
As of Feb 14, 2025
Lexeo Therapeutics, Inc [LXEO]
Source:
Company Overview
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | ( 212 ) 547-9879 |
| Industry | manufacturing |
| CEO | R. Nolan Townsend |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-105.8 |
| Net Income | $-98.3 |
| Net Cash | $-86.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -68.6% |
| Profit as % of Stockholder Equity | -84.2% |
Management Effectiveness
| Return on Equity | -84.2% |
| Return on Assets | -66.9% |
| Turnover Ratio | |
| EBITA | $-105.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $146.9 |
| Total Liabilities | $30.1 |
| Operating Cash Flow | $-81.2 |
| Investing Cash Flow | $-94.1 |
| Financing Cash Flow | $88.8 |
